:format(webp))
However, the rapid evolution of the industry—accelerated by the rise of Direct-to-Patient (DTP) clinical trials and the demand for advanced therapeutics - has fundamentally changed supply chain requirements.
This video explores Ireland's pivotal position in the global pharma ecosystem and details QuickSTAT’s specialized commitment and logistics infrastructure designed to support the market's expanding needs.
Discover the key factors that have positioned Ireland as a leading global cluster for pharmaceutical and biopharmaceutical innovation.
Understand the post-COVID rise of decentralized and DTP clinical trials, and how this paradigm shift impacts traditional supply chains.
Learn about the rigorous temperature-control and handling capabilities required to move high-value biopharma products safely in and out of the region.
Explore how QuickSTAT is expanding its local presence, resources, and operational expertise to seamlessly align with Ireland's growing pharma sector.
Loading iFrame
Press play to get started.
As a major exporter of life-saving medicines, Ireland's logistics infrastructure directly impacts global drug availability and clinical trial timelines.
The transition to DTP and decentralized trials requires highly specialized, agile courier networks to ensure patient compliance and safety.
Biopharmaceutical products manufactured in Ireland often require strict temperature management; robust logistics prevent costly product loss and preserve efficacy.
Aligning with a dedicated logistics partner ensures that Irish pharma hubs remain resilient against evolving global regulatory and distribution challenges.